X
KEY PRODUCTS
Details:
Bayer has granted non-exclusive rights to Dr. Reddy’s under the brand name Gantra. Vericiguat, a sGC stimulator, in India, is indicated, along with guideline-based medical therapy, in adults with symptomatic chronic heart failure with reduced ejection fraction.
Lead Product(s): Vericiguat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Gantra
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Bayer AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 05, 2024
Details:
Under the arrangement, Dr. Reddy’s will have exclusive rights to promote and distribute Sanofi’s wellestablished and trusted paediatric and adult vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U.
Lead Product(s): DTaP-IPV-HB-Hib
Therapeutic Area: Infections and Infectious Diseases Product Name: Hexaxim
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 27, 2024
Details:
Under the agreement, Dr. Reddy's has received exclusive rights to market and distribute a first-in-class innovative drug Lyfaquin in India. Developed by Pharmazz, Centhaquine is a resuscitative agent presently indicated for treating hypovolemic shock.
Lead Product(s): Centhaquine
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Lyfaquin
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Pharmazz
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 22, 2024
Details:
Versavo (bevacizumab) is a VEGF A inhibitor indicated for the treatment of cancers including metastatic colorectal cancer, advanced non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma & advanced cervical cancer.
Lead Product(s): Bevacizumab
Therapeutic Area: Oncology Product Name: Versavo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2024
Details:
DFD-29 (minocycline hydrochloride) has anti-inflammatory properties independent of their antibacterial activity that correlate with certain aspects of the pathophysiology. It is being evaluated for the treatment of papulopustular rosacea.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: DFD-29
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Journey Medical Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2024
Details:
Through the acquisition, Dr. Reddy expand its women’s health and dietary supplement branded portfolio, including MenoFit and MenoGlow probiotics to address the symptoms of menopause.
Lead Product(s): Bifidobacterium Animalis,Lactobacillus Gasseri,Lactobacillus Plantarum
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: MenoFit
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: MenoLabs
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 03, 2024
Details:
The financing would be utilized by Edity to further develop its technology platform for intracellular delivery of therapeutic proteins utilizing immune cells in multiple therapeutic areas including gene editing, rare genetic disorders, oncology and inflammation.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Edity Therapeutics
Deal Size: $2.0 million Upfront Cash: $2.0 million
Deal Type: Financing December 30, 2023
Details:
Under the agreement, Coya granted Dr. Reddy’s an exclusive license to commercialize COYA 302, a proprietary co-pack kit containing combination of low dose interleukin-2 and CTLA-4 Ig (abatacept) for the treatment of Amyotrophic Lateral Sclerosis.
Lead Product(s): Interleukin 2,Abatacept
Therapeutic Area: Neurology Product Name: COYA 302
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Coya Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 06, 2023
Details:
DFD-29 (minocycline hydrochloride) has anti-inflammatory properties independent of their antibacterial activity that correlate with certain aspects of the pathophysiology. It is being evaluated in phase 3 trials for the treatment of papulopustular rosacea.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: DFD-29
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Journey Medical Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
Semaglutide is a GLP-1 receptor agonist, which is being investigated in Phase 3 for the treatment of weight loss type 2 diabetes and chronic kidney disease.
Lead Product(s): Semaglutide
Therapeutic Area: Nutrition and Weight Loss Product Name: Semaglutide-Generic
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
